Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 273 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 273 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $140.55, for a total value of $38,370.15. Following the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at $1,055,108.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ingrid Delaet also recently made the following trade(s):

• On Thursday, March 21st, Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $145.06, for a total value of $725,300.00.
• On Monday, March 11th, Ingrid Delaet sold 200 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $140.00, for a total value of $28,000.00.
• On Friday, March 8th, Ingrid Delaet sold 1,800 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $140.03, for a total value of $252,054.00.
• On Thursday, February 29th, Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $135.51, for a total value of $36,994.23.

Neurocrine Biosciences Stock Performance

Shares of NBIX traded down $4.17 on Wednesday, reaching $139.02. The stock had a trading volume of 653,593 shares, compared to its average volume of 845,459. The firm has a market capitalization of $13.99 billion, a price-to-earnings ratio of 38.63 and a beta of 0.28. The company has a 50-day simple moving average of $137.63 and a 200-day simple moving average of $129.45. Neurocrine Biosciences, Inc. has a 12-month low of $89.04 and a 12-month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The firm’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.88 EPS. On average, analysts expect that Neurocrine Biosciences, Inc. will post 4.78 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $147.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, April 17th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Mizuho raised their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, February 8th. Guggenheim increased their price objective on Neurocrine Biosciences from $164.00 to $170.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. increased their price objective on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Six analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $147.88.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mather Group LLC. bought a new stake in shares of Neurocrine Biosciences in the 1st quarter worth $26,000. Headinvest LLC bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter worth $28,000. Lindbrook Capital LLC increased its holdings in shares of Neurocrine Biosciences by 85.0% in the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after purchasing an additional 96 shares in the last quarter. EdgeRock Capital LLC bought a new stake in shares of Neurocrine Biosciences in the 4th quarter worth $31,000. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in shares of Neurocrine Biosciences in the 4th quarter worth $33,000. Institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.